Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Spruce Biosciences logo — Advancing Treatments for Congenital Adrenal Hyperplasia and...

Spruce Biosciences

Advancing Treatments for Congenital Adrenal Hyperplasia and Other Rare Endocrine Disorders

Founded 2016 United States South San Francisco, United States 27 employees Post-IPO Equity Total: $161.60M Biopharma, Biotechnology +2

General Information

Company Name Spruce Biosciences
Founded Year 2016
Location United States South San Francisco, United States
Employees 27
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Post-IPO Equity
Business Model B2B, B2B2B
Revenue Model Product Sales, Licensing
Social

BounceWatch is an independent company data service, not affiliated with Spruce Biosciences. To contact Spruce Biosciences, visit sprucebiosciences.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Spruce Biosciences compare?

A PDF of Spruce Biosciences and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Spruce Biosciences soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Spruce Biosciences

Spruce Biosciences, established in 2016, is a United States-based clinical stage biopharmaceutical company. Their slogan, "Advancing Treatments for Congenital Adrenal Hyperplasia and Other Rare Endocrine Disorders," succinctly outlines their focus on developing pioneering therapies for rare endocrine diseases.

Specializing in the Biopharma, Biotechnology, Health Care, and Pharmaceutical industries, Spruce Biosciences has captured attention for its targeted approach to addressing unmet medical needs.

The company's recent financial milestone was a $53.60M post-IPO equity investment in February 2023, highlighting strong investor confidence. Key stakeholders include prestigious names such as Novo Holdings, 5AM Ventures, Abingworth, HealthCap, RiverVest, Rock Springs Capital, and Armistice Capital. This substantial backing underscores their strategic potential in the niche yet impactful area of endocrine disorder therapeutics.

Business keywords: Clinical Stage, Biopharmaceutical, Therapies for Rare Diseases, Endocrine System, Congenital Adrenal Hyperplasia, Hypothalamic-Pituitary-Adrenal Disorders, Rare Endocrine Disorders, Novel Therapies, Patient-Centric, Scientific Innovation, Quality of Life Improvement

Services & Products

Development of novel therapies
Clinical trials
Commercialization of pharmaceuticals
Enzyme replacement therapy
Targeted therapeutic delivery

Target Customers

Patients with neurological and endocrine disorders Healthcare providers Biotechnology partners Pharmaceutical companies Research institutions

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $53.60M 7
Novo Holdings 5AM Ventures Abingworth
Novo Holdings, 5AM Ventures +5
09 Feb 2023
Series B $88.00M 3
Abingworth HealthCap Omega Funds
Abingworth, HealthCap +1
20 Feb 2020
Series A $20.00M -
02 Jan 2016

Spruce Biosciences Alternatives & Competitors

View All Alternatives
Spruce Biosciences vs
Seelos Therapeutics, Inc.
Seelos Therapeutics, Inc. United States

A clinical-stage biopharmaceutical company focused on central nervous system disorders and rare dise...

Post-IPO Equity
8 employees
Biotechnology, Pharmaceutical
Compare Spruce Biosciences vs Seelos Therapeutics, Inc.
Spruce Biosciences vs
Aceragen
Aceragen United States

Aceragen is a rare disease company striving to restore a better life for patients and families.

Private Equity
2 employees
Biotechnology, Health Care
Compare Spruce Biosciences vs Aceragen
Spruce Biosciences vs
Leadiant Biosciences, Inc.
Leadiant Biosciences, Inc. United States

Pioneering innovative therapies for rare diseases, dedicated to enhancing patient quality of life.

55 employees
Biotechnology, Pharmaceutical
Also compare with: Spruce Biosciences vs Soleno Therapeutics, Inc. Soleno Therapeutics, Inc. View all alternatives

FAQ About Spruce Biosciences

Advancing Treatments for Congenital Adrenal Hyperplasia and Other Rare Endocrine Disorders
Spruce Biosciences was founded in 2016.
Spruce Biosciences is headquartered in South San Francisco, United States.
Spruce Biosciences operates in Biopharma, Biotechnology, Health Care and Pharmaceutical. Its work centres on Clinical Stage, Biopharmaceutical, Therapies for Rare Diseases and Endocrine System. Its customers include Patients with neurological and endocrine disorders, Healthcare providers and Biotechnology partners.
Spruce Biosciences has a B2B and B2B2B business model. Its revenue comes from Product Sales and Licensing.
Spruce Biosciences has approximately 27 employees.
Spruce Biosciences has completed 3 funding rounds, raising a total of $161.60M. The latest funding stage is Post-IPO Equity.
Spruce Biosciences offers: Development of novel therapies, Clinical trials, Commercialization of pharmaceuticals, Enzyme replacement therapy, Targeted therapeutic delivery.
Top alternatives and competitors to Spruce Biosciences include Seelos Therapeutics, Inc., Aceragen, Leadiant Biosciences, Inc., VectivBio, Soleno Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Spruce Biosciences and Seelos Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Spruce Biosciences, https://bouncewatch.com/company/spruce-biosciences, updated 9 April 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout